Literature DB >> 16439525

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Florence M Brunel1, Michael B Zwick, Rosa M F Cardoso, Josh D Nelson, Ian A Wilson, Dennis R Burton, Philip E Dawson.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 4E10 binds to a linear, highly conserved epitope within the membrane-proximal external region of the HIV-1 envelope glycoprotein gp41. We have delineated the peptide epitope of the broadly neutralizing 4E10 antibody to gp41 residues 671 to 683, using peptides with different lengths encompassing the previously suggested core epitope (NWFDIT). Peptide binding to the 4E10 antibody was assessed by competition enzyme-linked immunosorbent assay, and the K(d) values of selected peptides were determined using surface plasmon resonance. An Ala scan of the epitope indicated that several residues, W672, F673, and T676, are essential (>1,000-fold decrease in binding upon replacement with alanine) for 4E10 recognition. In addition, five other residues, N671, D674, I675, W680, and L679, make significant contributions to 4E10 binding. In general, the Ala scan results agree well with the recently reported crystal structure of 4E10 in complex with a 13-mer peptide and with our circular dichroism analyses. Neutralization competition assays confirmed that the peptide NWFDITNWLWYIKKKK-NH(2) could effectively inhibit 4E10 neutralization. Finally, to limit the conformational flexibility of the peptides, helix-promoting 2-aminoisobutyric acid residues and helix-inducing tethers were incorporated. Several peptides have significantly improved affinity (>1,000-fold) over the starting peptide and, when used as immunogens, may be more likely to elicit 4E10-like neutralizing antibodies. Hence, this study represents the first stage toward iterative development of a vaccine based on the 4E10 epitope.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439525      PMCID: PMC1367132          DOI: 10.1128/JVI.80.4.1680-1687.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Medicine. The need for a global HIV vaccine enterprise.

Authors:  Richard D Klausner; Anthony S Fauci; Lawrence Corey; Gary J Nabel; Helene Gayle; Seth Berkley; Barton F Haynes; David Baltimore; Chris Collins; R Gordon Douglas; Jose Esparza; Donald P Francis; N K Ganguly; Julie Louise Gerberding; Margaret I Johnston; Michel D Kazatchkine; Andrew J McMichael; Malegapuru W Makgoba; Giuseppe Pantaleo; Peter Piot; Yiming Shao; Edmund Tramont; Harold Varmus; Judith N Wasserheit
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

3.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

4.  Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Authors:  Catherine M Finnegan; Werner Berg; George K Lewis; Anthony L DeVico
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

6.  Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Authors:  Joseph G Joyce; William M Hurni; Michael J Bogusky; Victor M Garsky; Xiaoping Liang; Michael P Citron; Renee C Danzeisen; Michael D Miller; John W Shiver; Paul M Keller
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

Review 7.  The synthesis and study of side-chain lactam-bridged peptides.

Authors:  John W Taylor
Journal:  Biopolymers       Date:  2002       Impact factor: 2.505

8.  Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion.

Authors:  Gaetano Barbato; Elisabetta Bianchi; Paolo Ingallinella; William H Hurni; Michael D Miller; Gennaro Ciliberto; Riccardo Cortese; Renzo Bazzo; John W Shiver; Antonello Pessi
Journal:  J Mol Biol       Date:  2003-07-25       Impact factor: 5.469

9.  A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

Authors:  Michael B Zwick; Robert Kelleher; Richard Jensen; Aran F Labrijn; Meng Wang; Gerald V Quinnan; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more
  67 in total

1.  Wash-free, electrochemical platform for the quantitative, multiplexed detection of specific antibodies.

Authors:  Ryan J White; Hannah M Kallewaard; Wen Hsieh; Adriana S Patterson; Jesse B Kasehagen; Kevin J Cash; Takanori Uzawa; H Tom Soh; Kevin W Plaxco
Journal:  Anal Chem       Date:  2012-01-03       Impact factor: 6.986

2.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

3.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

Review 4.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

Review 5.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

6.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

7.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

8.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

Authors:  S Phogat; K Svehla; M Tang; A Spadaccini; J Muller; J Mascola; I Berkower; R Wyatt
Journal:  Virology       Date:  2007-12-26       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.